Sutro Biopharma STRO Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -120%+257pp | -154.5%+230pp | -175.7%— | -196.3%— | -376.9%— | |
| Net margin | -154.2%+215pp | -186.5%+180pp | -205.2%— | -199.8%— | -369.1%— | |
| EBITDA margin | -113.3%+253pp | -147.4%+225pp | -168.5%— | -189.1%— | -365.8%— | |
| Free cash flow margin | -152.2%+156pp | -172.9%+152pp | -210.7%— | -238.8%— | -308.1%— | |
| Returns | ||||||
| Return on assets | -54.5%+13.1pp | -68.1%-15.1pp | -65.5%— | -55.5%— | -67.7%— | |
| Efficiency | ||||||
| Asset turnover | 0.4×+0.2× | 0.4×+0.2× | 0.3×0.0× | 0.3×-0.1× | 0.2×-0.2× | |
| Liquidity | ||||||
| Current ratio | 3.1×+1.0× | 2×-0.6× | 2.5×-0.6× | 3.1×-0.3× | 2.2×-2.3× | |
| Quick ratio | 3.1×+1.0× | 2×-0.6× | 2.5×-0.6× | 3.1×-0.3× | 2.2×-2.3× | |
| Cash ratio | 1×+0.2× | 0.8×-0.7× | 0.9×-0.4× | 0.9×+0.2× | 0.8×0.0× | |
| Leverage | ||||||
| Debt-to-assets | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | 0.1×0.0× | |
| Per Share | ||||||
| Book value per share | -$5.11-65.7% | -$15.59-370% | -$1.03-176% | -$0.38-120% | -$3.09-293% | |
| Valuation | ||||||
| Market capitalization | $489.66M+624% | $98.57M-35.0% | $73.62M-73.8% | $69.46M-70.8% | $54.5M-84.3% | |
| Enterprise value | $429.61M-2,600% | $56.11M+464% | $25.35M-80.7% | $25.03M-85.6% | -$30.33M-110% | |
| Price / sales | 4.9×+3.9× | 1×-1.5× | 0.7×-1.0× | 0.7×-0.7× | 0.8×-1.4× | |
| EV / sales | 4.3×+4.6× | 0.5×+0.8× | 0.2×-0.6× | 0.2×-0.8× | -0.5×-2.5× | |
| Free cash flow yield | -31%+272pp | -179.8%-46.8pp | -302.4%— | -359.1%— | -375.6%— | |
| Earnings yield | -31.4%+331pp | -193.9%-43.9pp | -294.4%— | -300.5%— | -449.9%— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Sutro Biopharma's ratios come from?
- Every ratio is computed from Sutro Biopharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
